Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

Simona Sica, Jan Styczynski, Lidia Gil, Gloria Tridello, Per Ljungman, J. Peter Donnelly, Walter Van Der Velden, Hamdy Omar, Rodrigo Martino, Constantijn Halkes, Maura Faraci, Koen Theunissen, Krzysztof Kalwak, Petr Hubacek, Chiara Nozzoli, Franca Fagioli, Susanne Matthes, Miguel A. Diaz, Maddalena Migliavacca, Adriana BalduzziAgnieszka Tomaszewska, Rafael De La Camara, Anja Van Biezen, Jennifer Hoek, Simona Iacobelli, Hermann Einsele, Simone Cesaro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

115 Citazioni (Scopus)

Abstract

 The objective of this analysis was to investigate prognostic factors that influence the outcome of Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-based treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting.
Lingua originaleEnglish
pagine (da-a)794-802
Numero di pagine9
RivistaClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume57
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Epstein-Barr virus
  • hematopoietic stem cell transplantation
  • post-transplant lymphoproliferative disorder
  • prognostic model
  • risk factors

Fingerprint Entra nei temi di ricerca di 'Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation'. Insieme formano una fingerprint unica.

Cita questo